090-70-8511

Anti-dsDNA (Double Stranded DNA Antibodies) IgG, ELISA

Blood/ Plain blood (Red top) 6 mL, 1 tube

Serum, minimum volume 0.5 mL

Plastic tube

Hemolysis: Mild OK; Gross reject
Lipemia: Mild OK; Gross reject
Icteric: Mild OK; Gross reject

Serum: at 2-8°C for 14 days

090-70-8511

Anti-dsDNA (Double Stranded DNA Antibodies) IgG, ELISA

Test daily, at 12:00 p.m.

Received specimen to reported within 2 days

Molecular biology & Genetics, Laboratory Department
Tel.14168

7 days

090-70-8511

Anti-dsDNA (Double Stranded DNA Antibodies) IgG, ELISA

          The detection of autoantibodies against deoxyribonucleic acid (DNA) is essential in the diagnosis of systemic lupus erythematosus. Anti-dsDNA antibodies are found almost exclusively in systemic lupus erythematosus (SLE), also known as lupus erythematosus disseminatus. The prevalence of antibodies against dsDNA amounts to 20% to 90% depending on the detection method and disease activity. Antibodies against dsDNA are also occasionally detected in patients with other autoimmune diseases and infections and, in rare cases, in clinically healthy people. 85% of people in the latter group develop SLE within 5 years of initial detection of anti-dsDNA. 
          It is known to a large extent that anti-DNA antibodies play a role in the pathogenesis of SLE. During the course of disease, immunocomplexes of double-stranded DNA and the corresponding autoantibodies are deposited in the capillaries of the subcutis, the kidneys and other organs. Here they cause organ damage via activation of the complement system. There is increasing evidence that the primary target antigen of the pathogenically relevant autoantibodies is not “naked” DNA, but DNA complexed with nucleosomes.

< 100  IU/mL

          Antibodies against dsDNA are among the most important criteria for diagnosis of SLE due to their high specificity: 70% to 98% depending on the method of detection. A high concentration of autoantibodies against dsDNA is a very reliable marker for the diagnosis of SLE. The changes in the concentration of antibodies against dsDNA correlate with the activity of SLE nephritis. Therefore the Anti-dsDNA is not just significant for the prognosis of SLE, but also for monitoring the disease activity.
          However, SLE cannot be entirely excluded if anti-dsDNA antibodies are not detected. It must be taken into consideration that other serologically detectable autoantibodies may be responsible for the individual picture of the disease in addition to anti-dsDNA. Therefore, antibodies against nucleosomes, Sm, nRNP/Sm (U1-nRNP), SS-A (Ro), SS-B (La), ribosomal P-proteins and against other antigens of the cell nucleus should also be investigated.

Manufacturer’s reagent package insert, Anti-dsDNA-NcX ELISA (IgG) Test instruction, January 2013, EUROIMMUN, Lübeck, D-23560 Germany.